L Julian Haywood1, Barry R Davis2, Linda B Piller3, William C Cushman4, Jeffrey A Cutler5, Charles E Ford2, Lara M Simpson2, Alokananda Ghosh2, Elsayed Z Soliman6, Jackson T Wright7. 1. LAC+USC Medical Center, Keck School of Medicine, Los Angeles, CA, USA. 2. Coordinating Center for Clinical Trials, University of Texas School of Public Health, Houston, TX, USA. 3. Coordinating Center for Clinical Trials, University of Texas School of Public Health, Houston, TX, USA. Electronic address: Linda.B.Piller@uth.tmc.edu. 4. Preventive Medicine Section, Veterans Affairs Medical Center, University of Tennessee Health Science Center, USA. 5. Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD, USA. 6. Epidemiological Cardiology Research Center (EPICARE), Wake Forest University School of Medicine, Winston-Salem, NC, USA. 7. W T Dahms Clinical Research Unit, University Hospitals Case Medical Center, Cleveland, OH, USA.
Abstract
AIMS: Limited information is available on long-term antihypertensive and lipid-lowering therapy effects on hypertensive patients with atrial fibrillation/flutter (AF/AFL) compared to those without. AF/AFL at baseline or during the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (mean follow-up 4.9 years) markedly increased risk of stroke, heart failure, CHD, and all-cause mortality. We aimed to determine if AF/AFL continued to impact outcomes during post-trial follow-up (mean 3.8 years). METHODS: Patients were randomized to chlorthalidone, amlodipine, or lisinopril, and to pravastatin vs. usual care in the lipid-lowering trial (LLT). Of 31,473 available subjects, AF/AFL occurred in 854; 383/14,371 chlorthalidone (2.7%), 247/8565 amlodipine (2.9%), and 224/8537 lisinopril (2.6%). Post-hoc analyses utilized administrative databases for post-trial data. Individuals with AF/AFL were compared to those without during post-trial. Outcomes were analyzed by treatment groups for the antihypertensive and LLT trials. RESULTS: Among 854 AF/AFL participants, 491 (57.5%) died: 220 in-trial, 271 post-trial. Ten-year all-cause mortality rates for those with in-trial AF/AFL were similar for chlorthalidone and lisinopril, but lower for amlodipine (68, 66, and 49 per 100 persons, respectively); adjusted HR for amlodipine vs. chlorthalidone was 0.68 (95% CI, 0.54-0.87). Ten-year all-cause mortality rates were 57 vs. 65 per 100 persons (pravastatin vs. usual care); non-CVD mortality rates, 18 vs. 39 per 100 persons (pravastatin vs. usual care) (adjusted HR = 0.46, 95% CI, 0.24-0.86). CONCLUSION: Post-trial follow-up revealed continued deleterious AF/AFL effects. The amlodipine (ALLHAT) and pravastatin (ALLHAT-LLT) treatment groups showed lower all-cause and non-CVD mortality compared to the chlorthalidone and usual-care groups, respectively.
RCT Entities:
AIMS: Limited information is available on long-term antihypertensive and lipid-lowering therapy effects on hypertensivepatients with atrial fibrillation/flutter (AF/AFL) compared to those without. AF/AFL at baseline or during the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (mean follow-up 4.9 years) markedly increased risk of stroke, heart failure, CHD, and all-cause mortality. We aimed to determine if AF/AFL continued to impact outcomes during post-trial follow-up (mean 3.8 years). METHODS:Patients were randomized to chlorthalidone, amlodipine, or lisinopril, and to pravastatin vs. usual care in the lipid-lowering trial (LLT). Of 31,473 available subjects, AF/AFL occurred in 854; 383/14,371 chlorthalidone (2.7%), 247/8565 amlodipine (2.9%), and 224/8537 lisinopril (2.6%). Post-hoc analyses utilized administrative databases for post-trial data. Individuals with AF/AFL were compared to those without during post-trial. Outcomes were analyzed by treatment groups for the antihypertensive and LLT trials. RESULTS: Among 854 AF/AFL participants, 491 (57.5%) died: 220 in-trial, 271 post-trial. Ten-year all-cause mortality rates for those with in-trial AF/AFL were similar for chlorthalidone and lisinopril, but lower for amlodipine (68, 66, and 49 per 100 persons, respectively); adjusted HR for amlodipine vs. chlorthalidone was 0.68 (95% CI, 0.54-0.87). Ten-year all-cause mortality rates were 57 vs. 65 per 100 persons (pravastatin vs. usual care); non-CVD mortality rates, 18 vs. 39 per 100 persons (pravastatin vs. usual care) (adjusted HR = 0.46, 95% CI, 0.24-0.86). CONCLUSION: Post-trial follow-up revealed continued deleterious AF/AFL effects. The amlodipine (ALLHAT) and pravastatin (ALLHAT-LLT) treatment groups showed lower all-cause and non-CVD mortality compared to the chlorthalidone and usual-care groups, respectively.
Authors: B R Davis; J A Cutler; D J Gordon; C D Furberg; J T Wright; W C Cushman; R H Grimm; J LaRosa; P K Whelton; H M Perry; M H Alderman; C E Ford; S Oparil; C Francis; M Proschan; S Pressel; H R Black; C M Hawkins Journal: Am J Hypertens Date: 1996-04 Impact factor: 2.689
Authors: J E Udelson; C A DeAbate; M Berk; G Neuberg; M Packer; N K Vijay; J Gorwitt; W B Smith; M L Kukin; T LeJemtel; T B Levine; M A Konstam Journal: Am Heart J Date: 2000-03 Impact factor: 4.749
Authors: Kazem Rahimi; Jonathan Emberson; Paul McGale; William Majoni; Amal Merhi; Folkert W Asselbergs; Vera Krane; Peter W Macfarlane Journal: BMJ Date: 2011-03-16
Authors: Casper N Bang; Anders M Greve; Jawdat Abdulla; Lars Køber; Gunnar H Gislason; Kristian Wachtell Journal: Int J Cardiol Date: 2012-09-19 Impact factor: 4.164
Authors: Kristian Wachtell; Björn Hornestam; Mika Lehto; David J Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux Journal: J Am Coll Cardiol Date: 2005-03-01 Impact factor: 24.094
Authors: B M Psaty; T A Manolio; L H Kuller; R A Kronmal; M Cushman; L P Fried; R White; C D Furberg; P M Rautaharju Journal: Circulation Date: 1997-10-07 Impact factor: 29.690
Authors: Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah Journal: Circulation Date: 2015-07-28 Impact factor: 29.690
Authors: Vasilios Papademetriou; Linda B Piller; Charles E Ford; David Gordon; Thomas J Hartney; Therese S Geraci; Efrain Reisin; Brian Montgomery Sumner; Nathan D Wong; Chuke Nwachuku; Puneet Narayan; Julian Haywood; Gabriel Habib Journal: J Clin Hypertens (Greenwich) Date: 2003 Nov-Dec Impact factor: 3.738
Authors: L Julian Haywood; Barry R Davis; Linda B Piller; Lara M Simpson; Alokananda Ghosh; Paula T Einhorn; Charles E Ford; Jeffrey L Probstfield; Elsayed Z Soliman; Jackson T Wright Journal: J Natl Med Assoc Date: 2017-07-24 Impact factor: 1.798
Authors: Nisha Bansal; Dawei Xie; Daohang Sha; Lawrence J Appel; Rajat Deo; Harold I Feldman; Jiang He; Kenneth Jamerson; John W Kusek; Steven Messe; Sankar D Navaneethan; Mahboob Rahman; Ana Catherine Ricardo; Elsayed Z Soliman; Raymond Townsend; Alan S Go Journal: J Am Soc Nephrol Date: 2018-10-30 Impact factor: 10.121